🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you 🙏 YUO for the opportunity to present our work on ctDNA conversion dynamics and undetectable precystectomy ctDNA at the #SUO2024! Conversion dynamics matter and they predict different disease outcomes! Dr. John Sfakianos

Just published ☑️ Urology Gold Journal Single-port robotic-assisted nephroureterectomy with radical cystectomy and lymphadenectomy (unique case with a single kidney -> not requiring diversion). Reza Mehrazin, MD & Mohammed Almoflihi & Peter Wiklund 🆓-> doi.org/10.1016/j.urol…

Incredible opportunity and a great privilege to hear from Dr Gregg Semenza a #NobelPrize recipient (2019) on the topic of how cancers adapt to hypoxia and survive. HIF inhibitors are already used in renal cell carcinoma, and looking forward to the day when they will be

->📰 Now in BJUI onlinelibrary.wiley.com/share/author/Z… Novel immunotherapy-based neoadjuvant regimens for muscle-invasive bladder cancer may redefine the current standard of care. Accordingly, it is paramount for urologists to promptly recognize potential immune-related adverse events that

Important insights, 76% CSS after 12 years❗️ for NMIBC treated with RARC of whom ~35% were upstaged to MIBC at cystectomy‼️ Great work Neeraja!

Longitudinal tumor-informed ctDNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy. This study highlights the predictive & prognostic power of tumor-informed #ctDNA in #BladderCancer. Detectable pre-cystectomy ctDNA correlates with

Beyond the abstract on UroToday.com —now with an extra figure on ctDNA conversion dynamics! Our pre- and post-cystectomy ctDNA analysis offers insights into how radical cystectomy clears ctDNA in a subset of patients. Conversely, those with persistently detectable ctDNA that do not

These are rare tumors, yet, still captivate our minds! The 10% rule is far away from the truth! Just published in Urologic Clinics: Current management strategies for pheochromocytoma and paraganglioma! With excellent intra-op images ⏩authors.elsevier.com/a/1kjMFLO5gSWTx Nikhil Waingankar

It is a privilege to work and learn from such a pioneer in the field of bladder cancer Dr. John Sfakianos. We have made remarkable strides with PSA for prostate cancer—now is the time to advance in bladder cancer‼️ Tumor-informed ctDNA appears to be rising to the challenge.✅️

5 interactive posters in NMIBC session from our team Mount Sinai Department of Urology Reuben Ben-David ד''ר ראובן בן דוד Brenda Hug Kaushik Prabhav Kolanukuduru Thanks for the great Mentoring Dr. John Sfakianos #AUA25

Our current clinical staging modalities need additional biomarkers to recognize patients with high-risk NMIBC! ~40% had metastatic recurrence within 6 months after undergoing radical cystectomy! ctDNA is DEFINITELY showing promise in the field!

Up to now, we have looked at precystectomy ctDNA in a qualitative manner (detectable/undetectable). ⏩However, sub-categorizing the detectable group into low-burden and high-burden ctDNA, using mean tumor molecules/mL was able to define distinct groups within the detectable

#AUA25 was a great opportunity to present our findings Reza Mehrazin, MD on the utility of ctDNA in RCC, both in predicting disease recurrence and when comparing its diagnostic performance to conventional imaging studies. Thank you GU Oncology Now for highlighting these findings!

Could ctDNA allow relaxation of surveillance protocols after radical cystectomy, or offer clarity in equivocal cases? We evaluated the diagnostic accuracy of ctDNA vs. conventional imaging modalities among patients with urothelial carcinoma. Now on European Urology Oncology -》

Video in @UroToday: Zach Klaassen of Georgia Cancer Center hosts Reuben Ben-David ד''ר ראובן בן דוד of @icahnmountsinai to discuss the impact of pre-cystectomy circulating tumor DNA (ctDNA) on bladder cancer outcomes. Click here to watch the video: urotoday.com/video-lectures…

📺 Reuben Ben-David ד''ר ראובן בן דוד of Icahn School of Medicine at Mount Sinai, and Daniel Joyce, MD, of Vanderbilt University Medical Center, share the reasoning and findings of an analysis on the pathological and clinical features associated with preoperatively detectable #ctDNA: buff.ly/BZG3im3

Thank you Challenges in Laparoscopy & Robotics ( CILR ) for showing this case! The data for robotic RPLND continues to mature … current literature has shown that it is a great option for select patients with retroperitoneal tumors!